Oppenheimer Asset Management Inc. Buys New Stake in Boston Scientific Corporation $BSX

Oppenheimer Asset Management Inc. purchased a new position in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, HoldingsChannel.com reports. The firm purchased 25,283 shares of the medical equipment provider’s stock, valued at approximately $1,079,000.

Several other institutional investors have also bought and sold shares of BSX. Outfitters Financial LLC raised its position in shares of Boston Scientific by 0.5% during the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after buying an additional 110 shares in the last quarter. CYBER HORNET ETFs LLC lifted its position in Boston Scientific by 3.4% in the third quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock worth $391,000 after purchasing an additional 132 shares during the period. Gerber Kawasaki Wealth & Investment Management boosted its stake in Boston Scientific by 4.7% during the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock valued at $294,000 after purchasing an additional 139 shares in the last quarter. Northwestern Mutual Investment Management Company LLC raised its stake in shares of Boston Scientific by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock worth $4,516,000 after buying an additional 140 shares in the last quarter. Finally, Kingsview Wealth Management LLC boosted its stake in Boston Scientific by 2.4% during the fourth quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock valued at $578,000 after buying an additional 142 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on BSX. Needham & Company LLC lowered their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Barclays reduced their target price on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Robert W. Baird set a $56.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Royal Bank Of Canada dropped their price target on Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Finally, Weiss Ratings downgraded Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, July 7th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $71.62.

Insider Activity

In other Boston Scientific news, Director Cheryl Pegus bought 1,770 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael F. Mahoney purchased 186,240 shares of the stock in a transaction dated Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 204,322 shares of company stock valued at $9,939,221. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Stock Performance

Shares of BSX opened at $51.77 on Monday. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company has a 50-day moving average of $46.06 and a two-hundred day moving average of $59.11. The stock has a market cap of $75.02 billion, a price-to-earnings ratio of 20.96, a PEG ratio of 1.13 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the firm posted $0.75 earnings per share. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has authorized a share repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: An investment analysis argues that Boston Scientific could recover from its recent headwinds, supporting the view that the company’s diversified portfolio and structural-growth markets can reaccelerate over time. Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
• Positive Sentiment: Analyst consensus remains broadly favorable, with brokerage recommendations suggesting that BSX may merit portfolio consideration. However, the article cautions that sell-side ratings can be overly optimistic and should not be used as the sole investment signal. Brokers Suggest Investing in Boston Scientific
• Neutral Sentiment: Recent fund commentary highlights Boston Scientific’s second-quarter performance and the factors that affected the stock, giving investors additional context on the company’s operating challenges but offering no new company guidance or specific catalyst. Here’s What Hurt Boston Scientific Corporation in Q2
• Negative Sentiment: Parnassus Investments identified a growth slowdown in key Boston Scientific businesses. That raises concerns about near-term revenue momentum and could pressure the stock if weaker growth persists, despite the company’s recent earnings beat and positive longer-term outlook. Boston Scientific Faces Growth Slowdown in Key Businesses

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.